Wockhardt Limited — Important, 21-10-2024: General Updates

Wockhardt Limited has released its latest Investor Presentation, highlighting a remarkable 76% year-on-year growth in EBITDA and a 14% increase in total income to INR 2,879 Cr. The company is focusing on combating antimicrobial resistance with its novel antibiotics, ZAYNICH® and MIQNAF®, and anticipates strong growth in biosimilars, especially diabetes-related products. Wockhardt's strategic debt reduction and comprehensive R&D efforts position it well for future expansion in both domestic and global markets. Access the full presentation on their website.